教育經(jīng)歷：

1996年，劍橋大學(xué) 克萊爾學(xué)院，文學(xué)學(xué)士

1999年，倫敦大學(xué) 倫敦國(guó)王學(xué)院，醫(yī)學(xué)學(xué)士和外科學(xué)士

2010-2013年，奧塔哥大學(xué)，醫(yī)學(xué)博士

工作經(jīng)歷：

2018年-至今? 馬拉格漢醫(yī)學(xué)研究中心 臨床主任

2012年-至今? 首都和海岸區(qū)衛(wèi)生局? 血液學(xué)家顧問

2012年-2018年? 馬拉格漢醫(yī)學(xué)研究中心 臨床研究員

2011年? 倫敦蓋伊/圣托馬斯醫(yī)院? 血液學(xué)登記員

2007年-2010年? 馬拉格漢醫(yī)學(xué)研究中心 臨床研究員

2004年-2007年? 倫敦蓋伊/圣托馬斯醫(yī)院? 血液學(xué)登記員

2003年-2004年? 倫敦圣喬治醫(yī)院高級(jí)醫(yī)務(wù)官

2003年 圣詹姆斯大學(xué)利茲醫(yī)院 重癥監(jiān)護(hù)病房醫(yī)生

2002年? 倫敦蓋伊/圣托馬斯醫(yī)院 醫(yī)務(wù)高級(jí)干事

2001年-2002年? 漢諾威醫(yī)學(xué)院 住院醫(yī)生

1999年-2000年? 倫敦蓋伊/圣托馬斯醫(yī)院? 醫(yī)學(xué)與泌尿泌尿外科醫(yī)生

1999年? 倫敦格林尼治地區(qū)醫(yī)院 外科主任

?

癌癥免疫治療的臨床研究、血液腫瘤（主要為B細(xì)胞白血病和淋巴瘤）的診斷和管理。

1.?????? 已完成了新西蘭健康協(xié)會(huì)HRC資助的一項(xiàng)可行性試驗(yàn)“一項(xiàng)對(duì)乙酰氨基酚在發(fā)熱性中性粒細(xì)胞減少癥作用的隨機(jī)安慰劑對(duì)照試驗(yàn)”，擔(dān)任HRC資助的1/2期MELVAC試驗(yàn)的臨床顧問，該試驗(yàn)主要研究MIMR制造的自體細(xì)胞疫苗治療晚期黑色素瘤患者。

2.?????? 承擔(dān)了China-MWC項(xiàng)目：項(xiàng)目名稱：New methods to improve CAR T cell therapy for cancer（提升CAR T細(xì)胞抗腫瘤效果的新策略）；項(xiàng)目負(fù)責(zé)人：Rachel Perret, Robert Weinkove，參與人：Peng Li（李鵬）, Le Qin（秦樂,；資助金額：492946新幣；項(xiàng)目執(zhí)行期：2021.09-2023.08。

3.?????? 與李鵬組聯(lián)合開展了國(guó)家自然科學(xué)基金課題國(guó)際（地區(qū)）合作交流項(xiàng)目。項(xiàng)目名稱：含TLR共刺激結(jié)構(gòu)域的嵌合抗原受體T細(xì)胞的優(yōu)化及其抗腫瘤機(jī)制研究（項(xiàng)目編號(hào)：81961128003），資助直接經(jīng)費(fèi)300萬元，執(zhí)行期間2019.07.01-2022.06.31

4.?????? 與李鵬組聯(lián)合開展了廣州市對(duì)外科技合作項(xiàng)目，項(xiàng)目名稱：研發(fā)新型靶向惡性腫瘤并逆轉(zhuǎn)腫瘤微環(huán)境的細(xì)胞免疫治療（項(xiàng)目編號(hào)：201907010042），資助經(jīng)費(fèi)200萬元，執(zhí)行周期2019.04.01-2022.03.31。

2019年 新西蘭衛(wèi)生研究理事會(huì) 臨床醫(yī)生研究獎(jiǎng)學(xué)金

2018年10月 榮獲馬拉格漢醫(yī)學(xué)研究中心臨床醫(yī)生研究獎(jiǎng)學(xué)金

2012年11月 榮獲奧塔哥大學(xué)臨床研究博士獎(jiǎng)

1.??????? Burn OK, Farrand K, Pritchard T, Draper S, Tang CW, Mooney AH, Schmidt AJ, Yang SH, Williams GM, Brimble MA, Kandasamy M, Marshall AJ, Clarke K, Painter GF, Hermans IF, Weinkove R. Glycolipid-peptide conjugate vaccines elicit CD8+ T-cell responses and prevent breast cancer metastasis. Clin Transl Immunology. 2022 Jul 3;11(7):e1401.

2.??????? Jarvis EM, Collings S, Authier-Hall A, Dasyam N, Luey B, Nacey J, Painter GF, Delahunt B, Hermans IF, Weinkove R. Mucosal-Associated Invariant T (MAIT) Cell Dysfunction and PD-1 Expression in Prostate Cancer: Implications for Immunotherapy. Front Immunol. 2021 Oct 19;12:748741.

3.??????? Weinkove R, George P, Ruka M, Haira TH, Giunti G. Chimeric antigen receptor T-cells in New Zealand: challenges and opportunities. N Z Med J. 2021 Sep 17;134(1542):96-108.

4.??????? McQuilten ZK, Busija L, Seymour JF, Stanworth S, Wood EM, Kenealy M, Weinkove R; Australasian Leukaemia and Lymphoma Group (ALLG). Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia. Leuk Lymphoma. 2022 Mar;63(3):676-683.

5.??????? Weinkove R, McQuilten Z, Adler J, Agar M, Blyth E, Cheng A, Conyers R, Haeusler G, Hardie C, Jackson C, Lane S, Middlemiss T, Mollee P, Mulligan S, Ritchie D, Ruka M, Solomon B, Szer J, Thursky K, Wood E, Worth L, Yong M, Slavin M, Teh B. Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. Med. J. Aust. 2020; 212: 481-9.

6.??????? George P, Brown A & Weinkove R. B-cell prolymphocytic leukemia with a t(4;14) FGFR3/IGH translocation: response to ibrutinib. Pathology 2020; 52: 491 – 2.

7.??????? Grasso G, Field CS, Tang C-W, Ferguson PM, Compton BJ, Anderson RJ, Painter GF, Weinkove R, Hermans IF, Berridge MV. Vaccines adjuvanted with an NKT cell agonist induce effective T-cell responses in models of CNS lymphoma. Immunotherapy 2020; 12: 395 – 406

8.??????? Dasyam N, George P, Weinkove R. Chimeric antigen receptor T-cell therapies: Optimising the dose. Br J Clin Pharm 2020; 86: 1678 – 89

9.??????? George P, Dasyam N, Giunti G, Mester B, Bauer E, Andrews B, Perera T, Ostapowicz T, Frampton C, Li P, Ritchie D, Bollard CM, Hermans IF, Weinkove R. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE). BMJ Open 2020;10:e034629

10.???? Dickinson M, Weinkove R. Maintaining a fit T-cell compartment: lymphoma treatment sequencing in the era of CAR T-cell therapies. Int Med J 2019; 49: 1338.

11.???? Weinkove R, George P, Dasyam N, McLellan A. Selecting costimulatory domains for chimeric antigen rceptors: functional and clinical considerations. Clin Transl Immunology 2019; 8: e1049

12.???? Weinkove R, Bowden E, Wood C, Campion V, Carter J, Hall R, Weatherall M, Beasley R, Young P. A randomised controlled feasibility trial of paracetamol during febrile neutropenia in hemato-oncology patients. Leukemia & Lymphoma 2019; 60: 1540-7

13.???? Wheeler M, White G, Brockie S, Dickson M, Weinkove R. Flow cytometric analysis of mechanically disaggregated bone marrow trephine biopsies. Cytometry B Clin Cytom 2018; 27: 120-6.

14.???? Speir M, Authier-Hall A, Brooks CR, Farrand KJ, Compton BJ, Anderson RJ, Heiser A, Osmond TL, Tang CW, Berzofsky JA, Terabe M, Painter GF, Hermans IF, Weinkove R. Glycolipid-peptide conjugate vaccines enhance CD8+ T cell responses against human viral proteins. Sci Rep. 2017; 7: 14273.

15.???? Fischer K, Al-Sawaf O, Fink A, Dixon M, Bahlo J, Warburton S, Kipps TK, Weinkove R et al. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood 2017; 129: 2702-5.

16.???? Speir M, Hermans IH, Weinkove R. Engaging natural killer T cells as ‘universal helpers’ for vaccination. Drugs 2017; 7: 1-15.

17.???? Lucas N, Humble M, Sim D, Balm M, Carter JM, Weinkove R. Temporal changes in neutropenic blood culture isolates and disease associations: a single centre series of 1139 episodes. Int Med J 2017; 47: 962-5.

18.???? Mo A, McQuilten Z, Wood E, Weinkove R. Red cell transfusion thresholds in myelodysplastic syndromes: A clinician survey to inform future clinical trials. Int Med J 2017; 47: 695-8.

?